Schroder Investment Management Group boosted its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 5.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,257,545 shares of the biopharmaceutical company’s stock after buying an additional 173,379 shares during the period. Schroder Investment Management Group owned about 0.24% of Gilead Sciences worth $271,745,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Bank of Montreal Can bought a new stake in Gilead Sciences during the second quarter valued at $427,750,000. Investec Asset Management LTD bought a new stake in Gilead Sciences during the first quarter valued at $280,342,000. NN Investment Partners Holdings N.V. bought a new stake in Gilead Sciences during the first quarter valued at $180,268,000. Beacon Investment Advisory Services Inc. raised its stake in Gilead Sciences by 9,951.3% in the second quarter. Beacon Investment Advisory Services Inc. now owns 1,653,145 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 1,636,698 shares during the period. Finally, Emerald Acquisition Ltd. bought a new stake in Gilead Sciences during the second quarter valued at $129,175,000. Institutional investors and hedge funds own 77.94% of the company’s stock.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.21% during midday trading on Wednesday, hitting $81.61. The company’s stock had a trading volume of 10,553,274 shares. The company has a market cap of $107.70 billion, a P/E ratio of 7.16 and a beta of 1.06. The company has a 50-day moving average price of $79.31 and a 200 day moving average price of $86.01. Gilead Sciences Inc. has a 1-year low of $76.67 and a 1-year high of $111.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same quarter last year, the company posted $3.15 EPS. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences Inc. will post $11.77 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.30%. Gilead Sciences’s payout ratio is 16.56%.

GILD has been the subject of several analyst reports. Leerink Swann restated an “outperform” rating and issued a $123.00 target price on shares of Gilead Sciences in a report on Wednesday, May 25th. Morgan Stanley reduced their target price on Gilead Sciences from $107.00 to $103.00 and set an “equal weight” rating for the company in a report on Thursday, May 26th. Jefferies Group restated a “hold” rating and issued a $96.00 target price on shares of Gilead Sciences in a report on Friday, May 27th. Citigroup Inc. restated a “buy” rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Tuesday, May 31st. Finally, Gabelli initiated coverage on Gilead Sciences in a report on Wednesday, June 1st. They issued a “buy” rating and a $109.00 target price for the company. Nine investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $105.41.

In related news, Chairman John C. Martin sold 100,000 shares of the business’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the sale, the chairman now owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total value of $9,444,960.00. Following the sale, the chief executive officer now owns 1,170,963 shares in the company, valued at approximately $98,747,309.79. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.